Literature DB >> 11673571

The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis.

J de Seze1, D Devos, G Castelnovo, P Labauge, S Dubucquoi, T Stojkovic, D Ferriby, P Vermersch.   

Abstract

OBJECTIVE: To assess the prevalence of Sjögren syndrome (SS) in patients with primary progressive MS (PPMS).
BACKGROUND: SS may be considered in the differential diagnosis of MS. Age at onset and clinical presentation are similar in SS and PPMS. However, occurrence of SS in definite cases of PPMS has been recently reported.
METHODS: Proposed clinical and laboratory diagnostic criteria for SS were systematically assessed in 60 consecutive patients with PPMS. The authors questioned all patients about xerophthalmia and xerostomia, biopsied minor salivary glands, and performed a Schirmer test, a salivary gland scintigraphy, and anti-Ro (SSa) and anti-La (SSb) serologies.
RESULTS: Ten patients (16.6%) met four or more criteria for SS. This prevalence is higher than in the general population (1 to 5%) and implies that SS can mimic PPMS.
CONCLUSIONS: The authors propose that SS should be screened for systematically in patients with PPMS.

Entities:  

Mesh:

Year:  2001        PMID: 11673571     DOI: 10.1212/wnl.57.8.1359

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 2.  Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.

Authors:  Ibtisam Al-Hashimi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  [Neuroimmunology and rheumatology: overlap and differential diagnoses].

Authors:  C Trebst; T Kümpfel
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

4.  Neurological manifestations of connective tissue diseases mimicking multiple sclerosis.

Authors:  Sigliti-Henrietta Pelidou; Sotiris Giannopoulos; Sotiria Tzavidi; Niki Tsifetaki; Georgios Kitsos; Dimitrios Stefanou; Vassiliki Kostadima; Alexandros A Drosos; Athanassios P Kyritsis
Journal:  Rheumatol Int       Date:  2007-06-15       Impact factor: 2.631

Review 5.  Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants.

Authors:  Susan J Rogers; Christopher S Williams; Gustavo C Román
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Hospitalization Risks for Neurological Disorders in Primary Sjögren's Syndrome Patients.

Authors:  Radjiv Goulabchand; Audrey Gabelle; Xavier Ayrignac; Nicolas Malafaye; Pierre Labauge; Danièle Noël; Jacques Morel; Camille Roubille; Lucie Barateau; Philippe Guilpain; Thibault Mura
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

Review 7.  A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Per S Sorensen; Gary Cutter; Stephen C Reingold; Maria Trojano
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

8.  Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

Authors:  Andrew J Solomon; William Hills; Zunqiu Chen; James Rosenbaum; Dennis Bourdette; Ruth Whitham
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

9.  Neurological involvement in primary Sjögren syndrome: a focus on central nervous system.

Authors:  Manuela Morreale; Pasquale Marchione; Patrizia Giacomini; Simona Pontecorvo; Massimo Marianetti; Claudio Vento; Emanuele Tinelli; Ada Francia
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

10.  Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphy.

Authors:  Seval Erhamamcı; Bahriye Horasanlı; Ayşe Aktaş
Journal:  Mol Imaging Radionucl Ther       Date:  2014-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.